Skip to main content

Journal Club

Cerebrovascular

Trial of Early Minimally Invasive Removal of Intracerebral Hemorrhage

The New England Journal of Medicine | 2024

Rapid review note

Journal Club is a rapid, AI-assisted appraisal layer. It highlights study design, effect estimates, and practice relevance, but it is still a briefing, not a replacement for the paper.

For education only. Not medical advice.

Paper snapshot

Rapid study overview

Open paper

DOI

10.1056/NEJMoa2308440

PMID

N/A

PICO

Population

Adults with acute supratentorial intracerebral hemorrhage of 30 to 80 ml, randomized within 24 hours, including lobar and anterior basal ganglia hemorrhages.

Intervention

Early minimally invasive hematoma evacuation plus guideline-based medical management.

Comparator

Guideline-based medical management alone.

Outcomes

Utility-weighted modified Rankin score at 180 days, dichotomized functional outcome, 30-day death, and surgical safety events.

Design

Type

Multicenter adaptive randomized trial with Bayesian primary analysis

Randomized

Yes

Multicenter

Yes

Blinded

End-point adjudication reported; treatment assignment not blinded

Follow-up

180 days

Primary endpoint

Utility-weighted modified Rankin scale score at 180 days.

Secondary endpoints

  • Modified Rankin score 0 to 3 at 180 days
  • Death by 30 days
  • Postoperative rebleeding and hematoma reduction

Practice impact

What this means

ENRICH is the strongest recent surgical ICH trial signal, but it is not a blanket green light for every hemorrhage. The benefit appears to come mainly from early minimally invasive evacuation of lobar bleeds, so the right takeaway is targeted adoption, not indiscriminate surgery.

Bottom line

Early minimally invasive evacuation should be seriously considered for selected lobar intracerebral hemorrhages at experienced centers, but this trial does not justify treating all hemorrhage locations the same way.

Strength of evidence

moderate

Recommendation

consider change

Why it matters

  • The primary Bayesian efficacy end point crossed the prespecified superiority threshold.
  • Functional benefit and 30-day survival favored surgery overall, with the clearest signal in lobar hemorrhage.
  • The result is location-specific and technique-specific, so implementation needs careful patient selection.

What would change my mind

  • Replication in another randomized trial showing no meaningful benefit for lobar hemorrhage.
  • Prospective comparative data demonstrating that the signal disappears outside a few highly specialized centers.

Critical appraisal

How strong is the paper?

Methods critique

Risk of bias

Randomization supports internal validity, but the adaptive design changed enrollment to lobar hemorrhages only after 175 patients, which complicates a simple one-population interpretation.

Confounding

Random assignment should limit baseline confounding, although treatment effects may vary meaningfully by hemorrhage location and the procedure is tied to specialized surgical expertise.

Missing data

Not all enrolled patients had observed 180-day outcomes, so the Bayesian primary analysis used multiple imputation for missing modified Rankin scores.

Multiplicity

The trial reports overall, location-specific, and exploratory Bayesian analyses, so subgroup findings should be interpreted within the prespecified adaptive framework rather than as standalone proofs.

Notes

  • Benefit appeared to be driven by lobar rather than anterior basal ganglia hemorrhages.
  • The primary analysis used a Bayesian superiority threshold of 0.975.
  • The operation achieved substantial clot reduction, but the result remains technique and center dependent.

Stats check

NNT

Approximate NNT 11 for modified Rankin 0 to 3 at 180 days.

Effect sizes

  • The mean utility-weighted modified Rankin score at 180 days was 0.458 with surgery versus 0.374 with medical management, difference 0.084 (95% Bayesian credible interval 0.005-0.163).
  • Posterior probability of superiority for surgery was 0.981, above the prespecified 0.975 threshold.
  • The between-group difference was 0.127 for lobar hemorrhage but -0.013 for anterior basal ganglia hemorrhage.

Absolute effects

  • Modified Rankin 0 to 3 at 180 days occurred in 50.3% with surgery versus 41.0% with medical management.
  • Death by 30 days was 9.3% with surgery versus 18.0% with medical management.
  • Postoperative rebleeding with neurologic deterioration occurred in 3.3% of surgical patients.

Concerns

  • The apparent benefit was not uniform across hemorrhage locations.
  • The Bayesian adaptive design is valid but less intuitive than a conventional fixed design.
  • This was a specialized minimally invasive approach, not a generic statement about all ICH surgery.

External validity

Who it applies to

Patients with lobar intracerebral hemorrhage of trial-like size who can reach experienced minimally invasive surgical teams within 24 hours.

Who it does not

Patients with posterior fossa hemorrhage, thalamic or infratentorial hemorrhage, and likely many anterior basal ganglia cases where the benefit signal was not seen.

Generalizability notes

  • Applicability is strongest for lobar hemorrhage because enrollment adapted toward that group.
  • Results depend on access to the specific minimally invasive workflow and surgeon expertise.
  • This paper is more practice-relevant for centers that can offer early MIS ICH evacuation reliably.

Evidence trace

Source trace and metadata

Citations (4)

claim_id

methods_critique.missing_data

locator

p. 6

claim_id

stats_check.effect_sizes

locator

p. 1

claim_id

stats_check.absolute_effects

locator

p. 7 Table 2

claim_id

practice_impact.bottom_line

locator

p. 1

Metadata

Generated at

2026-03-08T15:40:00-05:00

Version

manual-pdf-repair-v1